Site-directed mutations in the lanthipeptide mutacin 1140.
about
Variable characteristics of bacteriocin-producing Streptococcus salivarius strains isolated from Malaysian subjectsLanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical productionBioengineering Lantibiotics for Therapeutic SuccessAdvances in the Microbiome: Applications to Clostridium difficile InfectionMultipronged approach for engineering novel peptide analogues of existing lantibiotics.Genome database mining for the discovery of novel lantibiotics.The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes.Biosynthesis and transport of the lantibiotic mutacin 1140 produced by Streptococcus mutans.Draft Genome Sequence of Oral Bacterium Streptococcus mutans JH1140.Improving the attrition rate of Lanthipeptide discovery for commercial applications.Two Flavoenzymes Catalyze the Post-Translational Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine during NAI-107 Biosynthesis.Incorporation of Nonproteinogenic Amino Acids in Class I and II Lantibiotics.Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2.Screening for inhibitors of mutacin synthesis in Streptococcus mutans using fluorescent reporter strains.Fighting biofilms with lantibiotics and other groups of bacteriocins.OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.
P2860
Q21558804-BEAFD7F5-C016-41FA-B8AD-352018EE84B5Q26748638-313BD2A6-3635-438C-8E85-8F440A2E666FQ26774123-8A3C9BCA-8807-4B3A-B06A-68F8585CE89CQ28066362-91BE554F-7B1A-414F-AFFD-2186FF70EA11Q38500614-32E1E778-AAB5-44C5-BE2F-12793AA6384EQ38901217-FEB5F6B8-401D-4FBB-920E-537A2A6CF27FQ39097534-B93296E6-90FC-4600-A2DA-4DAAFE121913Q39109460-4408371A-09FC-4D6C-A3E2-23D366219D2FQ41553325-D3C5AA88-1880-44E3-8374-5E3B5BC04B9FQ42210834-E88F90B7-CC9B-4D0A-B8A6-A8BD0F6008B7Q47383314-0112D301-7375-43E7-9A01-CCB8DDE41B0AQ48108610-5F5EDE2B-4439-4494-BED5-9137DCC269E2Q50033661-3BC483AC-A860-46D8-9C5B-80EF7DB3487CQ51005035-B968DAC0-85E7-44A5-A39C-877267978270Q52608578-B3406427-3866-47A2-8EAD-C9ED3667DF48Q52739856-BD0EB3A9-CFEA-4FD3-988C-6FF5E976ED65Q55042084-3498E09C-5A20-4026-AF0D-D47530BF1553Q55223927-CBEB384E-A0CF-40EF-B7FB-74FC1C59DBE1Q55307893-2B822F49-72C5-4657-A045-772F750DABB2
P2860
Site-directed mutations in the lanthipeptide mutacin 1140.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Site-directed mutations in the lanthipeptide mutacin 1140.
@ast
Site-directed mutations in the lanthipeptide mutacin 1140.
@en
Site-directed mutations in the lanthipeptide mutacin 1140.
@nl
type
label
Site-directed mutations in the lanthipeptide mutacin 1140.
@ast
Site-directed mutations in the lanthipeptide mutacin 1140.
@en
Site-directed mutations in the lanthipeptide mutacin 1140.
@nl
prefLabel
Site-directed mutations in the lanthipeptide mutacin 1140.
@ast
Site-directed mutations in the lanthipeptide mutacin 1140.
@en
Site-directed mutations in the lanthipeptide mutacin 1140.
@nl
P2093
P2860
P356
P1476
Site-directed mutations in the lanthipeptide mutacin 1140
@en
P2093
Adam Guerrero
Charlotte A Allen
Jeffrey D Hillman
Leif Smith
Shaorong Chen
Shawanda Wilson-Stanford
P2860
P304
P356
10.1128/AEM.00704-13
P407
P577
2013-04-19T00:00:00Z